Peter Weiden
Psychiatry · Chicago, ILNPI 1386754125
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (46.8%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 27.3% of the total. 2025 is the largest year on record at $236,649, more than ten times the $66 reported in 2019. Among psychiatry clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 477 payments — averaging $921.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$120K
- Alkermes, Inc.$103K
- Neurocrine Biosciences, Inc.$84K
- Teva Pharmaceuticals USA, Inc.$54K
- Boehringer Ingelheim$29K
- Luye Pharma (USA) Ltd.$27K
- plus $21K from 8 others
Across 93 payments — averaging $5428.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$347K
- Vanda Pharmaceuticals Inc.$68K
- Boehringer Ingelheim International GmbH$53K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$38K
What the payments were for
- Consulting fees$205,62247%
- Speaking & faculty fees$186,31142%
- Travel & lodging$35,7718%
- Food & beverage$11,8523%
- Education$100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 110 | $120,156 |
| Alkermes, Inc. | 97 | $103,387 |
| Neurocrine Biosciences, Inc. | 104 | $84,293 |
| Teva Pharmaceuticals USA, Inc. | 56 | $54,162 |
| Boehringer Ingelheim | 38 | $29,437 |
| Luye Pharma (USA) Ltd. | 28 | $27,190 |
| Vanda Pharmaceuticals Inc. | 29 | $20,542 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $78 |
| Indivior Inc. | 1 | $66 |
| Acadia Pharmaceuticals Inc | 2 | $64 |
| AbbVie | 3 | $59 |
| Johnson & Johnson | 2 | $49 |
| Otsuka America Pharmaceutical, Inc. | 2 | $44 |
| Lilly USA, LLC | 2 | $41 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$109,127
- ARISTADA$103,091
- INGREZZA$80,986
- COBENFY$57,019
- UZEDY$34,372
- ERZOFRI EXTENDED-RELEASE$26,954
- Fanapt$19,959
- ARISTADA INITIO$13,098
- Austedo XR$1,585
How this compares
$439,566 in reported general payments places this provider in the 95th percentile of 1,344 psychiatry providers in Illinois.
Other psychiatry in Chicago
- Mitchell GlaserChicago$752K
- Michelle DeesChicago$289K
- Jeffrey RadoChicago$208K
- K Ranga KrishnanChicago$92K
- Richard BaerChicago$44K
- Adam GoldenbergChicago$23K
- Olusola AjiloreChicago$21K
- Emil CoccaroChicago$20K
- Guarava AgarwalChicago$20K
- Jon GrantChicago$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.